var data={"title":"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/contributors\" class=\"contributor contributor_credentials\">Mary A Albrecht, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 25, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles). Primary VZV infection results in the diffuse vesicular rash of varicella or chickenpox.</p><p>Clinical resolution is followed by the establishment of latent infection within the sensory dorsal root ganglia. Reactivation of this neurotropic virus leads to herpes zoster, or shingles, a painful, unilateral vesicular eruption in a restricted dermatomal distribution [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>The pathogenesis, epidemiology, and sequelae of herpes zoster will be reviewed here. The clinical manifestations, treatment and prevention of this infection, manifestations during pregnancy, and issues related to chickenpox are discussed separately. (See <a href=\"topic.htm?path=postherpetic-neuralgia\" class=\"medical medical_review\">&quot;Postherpetic neuralgia&quot;</a> and <a href=\"topic.htm?path=vaccination-for-the-prevention-of-shingles-herpes-zoster\" class=\"medical medical_review\">&quot;Vaccination for the prevention of shingles (herpes zoster)&quot;</a> and <a href=\"topic.htm?path=varicella-zoster-virus-infection-in-pregnancy\" class=\"medical medical_review\">&quot;Varicella-zoster virus infection in pregnancy&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">&quot;Clinical manifestations of varicella-zoster virus infection: Herpes zoster&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Incidence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Overall, the CDC estimates that approximately 30 percent of persons in the United States will experience zoster during their lifetimes [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/3,4\" class=\"abstract_t\">3,4</a>]. In the United States, herpes zoster occurs in nearly one million individuals annually, causing substantial morbidity [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/5\" class=\"abstract_t\">5</a>]. The cumulative lifetime incidence is approximately 10 to 20 percent of the population [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/6\" class=\"abstract_t\">6</a>]. Incidence rates progressively increase with age, presumably due to the decline in virus (VZV)-specific cell-mediated immunity [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/5,7-11\" class=\"abstract_t\">5,7-11</a>].</p><p>The incidence of herpes zoster appears to be increasing [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/5,12-14\" class=\"abstract_t\">5,12-14</a>]. As an example, in a population-based cohort study of 8017 patients with herpes zoster in Minnesota, the incidence rate was 0.76 per 1000 person-years from 1945 to 1949, and increased to 3.15 per 1000 person-years from 2000 to 2007 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/13\" class=\"abstract_t\">13</a>]. In a large study of veterans, the annual incidence rates significantly increased from 3.1 episodes per 1000 veterans in 2000 to 5.2 in 2007 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/12\" class=\"abstract_t\">12</a>]. The reason for this increase is unclear. </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Age is the most important risk factor for the development of zoster (<a href=\"image.htm?imageKey=ID%2F79262\" class=\"graphic graphic_figure graphicRef79262 \">figure 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/3,15\" class=\"abstract_t\">3,15</a>]. One study demonstrated that zoster incidence increased 10-fold with age when comparing children less than 10 years of age to persons aged 80 to 89 years; a dramatic increase in disease rates begins to occur after 50 years of age [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/16\" class=\"abstract_t\">16</a>]. It is estimated that approximately 50 percent of persons who live to age 85 will have an episode of zoster [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/8\" class=\"abstract_t\">8</a>]. Other studies from the United States and Europe also demonstrate that older patients with VZV account for the majority of medical consultations and hospitalizations for this diagnosis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/7,9,10\" class=\"abstract_t\">7,9,10</a>].</p><p>In addition, among persons with zoster, the risk for postherpetic neuralgia (PHN) increases with age. In one study, the risk for experiencing PHN increased 27-fold among patients aged &gt;50 years compared with those &lt;50 years [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/17\" class=\"abstract_t\">17</a>]. In another study, PHN occurred in 18 percent of all adult patients with herpes zoster, but in more than one-third of those aged 79 years or older [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Physical trauma appears to be a risk factor for herpes zoster, particularly cranial herpes zoster. In an age-matched case-control study that used Medicare data, patients &ge;65 years of age who developed herpes zoster were 3.4 times more likely than controls to have experienced trauma during the week prior to herpes zoster onset [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/18\" class=\"abstract_t\">18</a>]. Patients who had cranial herpes zoster were more than 25 times as likely as controls to have had cranial trauma during the week prior to herpes zoster onset.</p><p>Other risk factors for developing herpes zoster include underlying malignancy, depression, disorders of cell-mediated immunity, and chronic lung or kidney disease [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/19,20\" class=\"abstract_t\">19,20</a>] &#160;</p><p>A careful history and physical examination should be performed in a patient who presents with herpes zoster; however, an episode of herpes zoster itself should not prompt an evaluation for an occult cancer in an otherwise healthy individual. HIV serologic testing may be considered in patients who have never had routine testing and are at risk for HIV acquisition [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Immunocompetent hosts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The natural history of herpes zoster varies depending on the host. Reactivation appears to be influenced by age-related immunosenescence, disease-related immunocompromise, or iatrogenic immunosuppression. As noted above, increasing age is the leading risk factor for the development of herpes zoster. The following observations have also been made:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An excess of zoster cases has been observed among women, even when controlling for age [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One study suggested that the incidence of herpes zoster was significantly lower in black versus white study participants [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/23\" class=\"abstract_t\">23</a>]. However, these findings may be partially explained by the results of one survey that demonstrated a higher proportion of elderly black persons have not had primary varicella and thus are not at risk for zoster [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/24\" class=\"abstract_t\">24</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Approximately 1 to 4 percent of individuals will experience a second episode of herpes zoster, although this is more common in the immunocompromised host [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/5,6,9\" class=\"abstract_t\">5,6,9</a>].</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Immunocompromised patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunocompromised patients are at increased risk of VZV reactivation, including transplant recipients [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/25-32\" class=\"abstract_t\">25-32</a>], patients receiving selected immunomodulator therapies [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/33-39\" class=\"abstract_t\">33-39</a>], and HIV-infected patients [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/40-42\" class=\"abstract_t\">40-42</a>]. The rate of complications (eg, disseminated disease, ocular involvement) is also significantly higher in those who are immunosuppressed [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Transplant patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence of herpes zoster in solid organ transplant recipients is 10- to 100-fold higher than in the general population, ranging from 1 to 12 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/27\" class=\"abstract_t\">27</a>]. The risk of reactivation is also higher in older immunocompromised patients, as noted in immunocompetent populations [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective review of 239 patients undergoing lung transplantation, 29 patients developed zoster with a calculated incidence of 55 per 1,000 person-years of follow-up [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/43\" class=\"abstract_t\">43</a>]. Postherpetic neuralgia occurred in 20 percent of patients. No clear risk factor for the development of herpes zoster was identified; CMV prophylaxis with <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> was protective.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another retrospective review of 612 renal transplant recipients, 37 subjects developed herpes zoster for a time-adjusted incidence of 11 percent at four years of follow-up [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/44\" class=\"abstract_t\">44</a>]. Patients who were VZV-seronegative at the time of transplant had a threefold increased risk of developing herpes zoster compared to those who were seropositive.</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Autoimmune disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is an increased risk of herpes zoster in patients with underlying autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease), particularly due to the use of immunosuppressive therapies such as glucocorticoids, nonbiologic disease-modifying antirheumatic drugs (DMARDs), and tumor necrosis factor (TNF)-alpha inhibitors [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/34-38,45-48\" class=\"abstract_t\">34-38,45-48</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A multicenter cohort study performed in the United States compared the incidence of herpes zoster in 25,742 patients with rheumatoid arthritis or another autoimmune disease initiating nonbiologic DMARDs and 33,324 patients initiating a TNF-alpha inhibitor [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/48\" class=\"abstract_t\">48</a>]. Baseline use of glucocorticoids at a dose of &ge;10 <span class=\"nowrap\">mg/kg</span> per day <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> equivalents was associated with an increased risk of herpes zoster (adjusted hazard ratio 2.13, 95% CI 1.64-2.75) compared with no baseline use.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the same study, patients who initiated a TNF-alpha inhibitor were not at higher risk for herpes zoster than patients initiating nonbiologic DMARDs, and no differences in risk were observed among <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a>, <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, and <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> recipients [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In contrast, an earlier smaller study showed that use of <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> or <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> was associated with a moderately increased risk of herpes zoster (hazard ratio 1.82, 95% CI 1.05-3.15) compared with nonbiologic DMARDs [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A nested retrospective case-control study included 18,000 patients with inflammatory bowel disease who were treated with glucocorticoids <span class=\"nowrap\">and/or</span> the nonbiologic DMARDs, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> or 6-mercaptopurine [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/46\" class=\"abstract_t\">46</a>]. The incidence of herpes zoster was significantly increased with both glucocorticoids and <span class=\"nowrap\">azathioprine/6-mercaptopurine</span> (adjusted odds ratio 1.5 and 3.1, respectively).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A retrospective Veterans Affairs cohort study, involving 20,357 patients with rheumatoid arthritis, found that those who received treatment for either moderate disease (eg, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>) or severe disease (eg, TNF-alpha inhibitors) were at increased risk of developing herpes zoster [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/19\" class=\"abstract_t\">19</a>]. </p><p/><p>The risk of herpes zoster in patients receiving a TNF-alpha inhibitor is discussed in greater detail separately. (See <a href=\"topic.htm?path=tumor-necrosis-factor-alpha-inhibitors-bacterial-viral-and-fungal-infections#H12\" class=\"medical medical_review\">&quot;Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections&quot;, section on 'Herpes zoster'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">HIV infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV-infected patients are at greater risk of developing herpes zoster compared with those who are HIV-uninfected. As examples: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The interaction of VZV with HIV-1 was evaluated in a cohort of 786 men who have sex with men (MSM), 287 were HIV-positive and 499 were HIV-negative [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/40\" class=\"abstract_t\">40</a>]. The incidence of zoster was higher in HIV-infected men (29.4 <span class=\"nowrap\">cases/1000</span> person-years versus 2.0 <span class=\"nowrap\">cases/1000</span> person-years). The overall age-adjusted relative risk (RR) for developing zoster in HIV-infected men was 16.9 (95% CI 8.7-32.6), and the risk was not associated with the duration of HIV infection. Herpes zoster infection did not predict more rapid progression to AIDS.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A prospective study of 966 MSM also found a higher incidence of herpes zoster in HIV-infected versus HIV-uninfected men (51.51 per 1000 person-years versus 3.31 per 1000 person-years), and recurrences were only documented in HIV-infected individuals (26 percent) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/41\" class=\"abstract_t\">41</a>]. The incidence of zoster increased with decreasing CD4 cell counts (31.2 per 1000 person-years for a CD4 count &gt;500 <span class=\"nowrap\">cells/microL,</span> 47.2 per 1000 person-years for 200 to 499 <span class=\"nowrap\">cells/microL,</span> and 97.5 per 1000 person-years for &lt;200 <span class=\"nowrap\">cells/microL)</span>.</p><p/><p>The incidence of herpes zoster has remained greater in HIV-infected individuals even after the introduction of potent antiretroviral therapy (ART). This was illustrated in a study evaluating 7167 cases of herpes zoster among 91,044 individuals [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/49\" class=\"abstract_t\">49</a>]. Although there was an overall decline in the incidence of herpes zoster that was attributed to ART (2955 cases per 100,000 person-years between 1992 and 1996 versus 628 cases per 100,000 person-years between 2009 and 2011), the incidence of herpes zoster remained significantly higher in patients with HIV compared with the general population (overall standardized incidence ratio 2.7, 95% CI 2.6-2.9). In HIV-infected patients who were treatment-na&iuml;ve, the risk of developing herpes zoster was increased during the first six months after initiating ART.</p><p>HIV-infected children who develop chickenpox have a higher incidence of developing herpes zoster and are more likely to have recurrent zoster; a lower CD4 cell count enhances this risk as shown in a prospective study of VZV infection in 61 HIV-infected children with CD4 cell ranges between 20 and 24 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/42\" class=\"abstract_t\">42</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Of 30 children who had primary varicella after the age of one year, 8 (27 percent) developed zoster.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Zoster developed an average of 1.9 years after varicella occurred.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children with CD4 cells &lt;15 percent when they developed chickenpox were at a higher risk for zoster, with an incidence of 467 cases per 1000 person-years.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Four of eight children with zoster (50 percent) experienced recurrences.</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Impact of varicella vaccine on incidence of herpes zoster</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the licensure of <a href=\"topic.htm?path=varicella-virus-vaccine-drug-information\" class=\"drug drug_general\">varicella vaccine</a>, concerns were raised that immunization might lead to an increased risk of vaccine-associated herpes zoster, particularly in immunocompromised children. Other experts raised the possibility that widespread varicella immunization in childhood may increase the incidence of herpes zoster in the general population due to decreased circulation of wild-type virus and a decline in T-cell immunity [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/50\" class=\"abstract_t\">50</a>]. Neither of these concerns has materialized.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vaccine associated zoster &mdash; The incidence of post-vaccination zoster was examined in a study of 548 children with acute lymphocytic leukemia who received the Oka live attenuated VZV vaccine. Zoster developed in 13 subjects (2.4 percent) during a mean follow-up interval of 4.1 years [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/51\" class=\"abstract_t\">51</a>]. In a subgroup analysis that matched 96 vaccinated subjects to those who had prior natural varicella infection, the incidence of zoster was lower in the immunized group (4 compared to 15 cases in those subjects with natural infection).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Zoster in the general population &mdash; Data suggest that the vaccine-induced decline in varicella disease has not led to an increase in herpes zoster in the general population [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/13,52-54\" class=\"abstract_t\">13,52-54</a>]. As examples:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The Centers for Disease Control and Prevention collaborated with an HMO in Washington State to monitor the incidence rates of varicella and herpes zoster before and after vaccine licensure [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/52\" class=\"abstract_t\">52</a>]. The incidence of varicella decreased between 1995 and 2002 (from 2.63 cases to 0.92 <span class=\"nowrap\">cases/100</span> person-years), but the incidence of herpes zoster remained stable. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In a retrospective study of Medicare claims from 1992 to 2010, a total of 281,317 incident cases of herpes zoster occurred [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/53\" class=\"abstract_t\">53</a>]. The herpes zoster incidence increased 39 percent over this time period from 10.0 per 1000 person-years in 1992 to 13.9 per 1000 person-years in 2010. This increase in HZ incidence preferentially occurred in individuals older than 65 years and the widespread use of the <a href=\"topic.htm?path=varicella-virus-vaccine-drug-information\" class=\"drug drug_general\">varicella vaccine</a> after 1996 did not appear to affect this increase.</p><p/><p>Other issues related to varicella vaccination are discussed separately. (See <a href=\"topic.htm?path=vaccination-for-the-prevention-of-chickenpox-primary-varicella-infection\" class=\"medical medical_review\">&quot;Vaccination for the prevention of chickenpox (primary varicella infection)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H894087829\"><span class=\"h1\">TRANSMISSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>People with herpes zoster can spread varicella-zoster virus (VZV) to those who have not had varicella and have never received the varicella (chickenpox) vaccine. The virus typically spreads through direct contact with the active herpes zoster lesions [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/55\" class=\"abstract_t\">55</a>]. The lesions are considered infectious until they dry and crust over.</p><p>In addition, airborne transmission of VZV from individuals with localized zoster has been described in several reports [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/56-59\" class=\"abstract_t\">56-59</a>]. As an example, a small outbreak of varicella occurred in a long-term care facility after a nursing home resident developed herpes zoster (index case) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/59\" class=\"abstract_t\">59</a>]. Of the three individuals who subsequently developed varicella (one health care worker and two nursing home residents), none had direct contact with the index case. However, an analysis of viral isolates demonstrated a unique mosaic genotype VZV strain (West Virginia) that was present in all cases. Although environmental sampling for VZV DNA demonstrated widespread contamination, airborne transmission was still suspected.</p><p>VZV has also been detected in saliva. In a study of 54 patients with zoster who were treated with <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>, VZV DNA was identified in saliva of all patients on the first day of treatment, and resolved in 82 percent of patients by day 15 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/60\" class=\"abstract_t\">60</a>]. In addition, infectious VZV was isolated from one of two patients whose saliva was cultivated in tissue culture. However, it is not known whether saliva is a vehicle of VZV transmission.</p><p>A detailed discussion of VZV transmission in the hospital setting is found elsewhere. (See <a href=\"topic.htm?path=prevention-and-control-of-varicella-zoster-virus-in-hospitals\" class=\"medical medical_review\">&quot;Prevention and control of varicella-zoster virus in hospitals&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the early 1900s, many viewed &quot;shingles&quot; as a viral illness that was acquired from person-to-person contact, similar to &quot;chickenpox.&quot; The hypothesis that zoster was secondary to reactivation of latent varicella-zoster virus (VZV) infection was first proposed in 1965 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/61\" class=\"abstract_t\">61</a>]. The precise mechanisms involved in the establishment of viral latency following primary VZV infection have been an ongoing focus of investigation.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Dissemination and immune evasion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During the initial phase of varicella, VZV inoculates the nasopharyngeal lymphoid tissue through airborne viral droplets in a susceptible host. This is followed by rapid spread to regional lymphoid tissue with preferential infection of tonsillar memory CD4+ T cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/62,63\" class=\"abstract_t\">62,63</a>]. Susceptibility of tonsillar T cells to VZV suggests that this cellular population may be an important target during initial infection.</p><p>The exact mechanism by which VZV is transported from the nasopharynx to regional lymph nodes has not been elucidated, but appears to involve cell-associated viremia in the form of migrating T-cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/64\" class=\"abstract_t\">64</a>]. VZV causes productive infection of activated CD4+ T cells, resulting in downregulation of major histocompatibility complex (MHC) class I expression [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/62,64,65\" class=\"abstract_t\">62,64,65</a>]. Downregulation of MHC class I expression enables the virus to evade the immune system. Preferential infection of CD4 T cells, expressing skin homing markers, may enhance transport of VZV to cutaneous epithelia. </p><p>The prolonged incubation period, prior to the onset of skin lesions, may reflect the time required for VZV to overcome local immune-mediated barriers, including alpha interferon (IFN-a) production by epidermal cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/62,65\" class=\"abstract_t\">62,65</a>]. During acute infection, viremia uniformly occurs as shown by detection of VZV DNA in serum, peripheral blood mononuclear cells, and in the characteristic lesions of herpes zoster [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/66\" class=\"abstract_t\">66</a>]. VZV DNA has also been demonstrated in human saliva among patients with acute symptoms of herpes zoster [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/60\" class=\"abstract_t\">60</a>] and persists for many years after clinical illness [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/67\" class=\"abstract_t\">67</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Latency and reactivation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cell-free virus, which is present only in skin vesicles, infects nerve endings in skin and migrates along sensory axons to establish latency in neurons within the regional ganglia [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/64,68-70\" class=\"abstract_t\">64,68-70</a>]. VZV proteins accumulate preferentially in the cytoplasm of neurons during latency, but migrate to the nucleus during productive infection [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/71\" class=\"abstract_t\">71</a>]. Once reactivation occurs, virus can spread to other cells within the ganglion to involve multiple sensory neurons and thereby establish infection of the skin [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/2\" class=\"abstract_t\">2</a>].</p><p>A guinea pig model has been developed to examine viral latency and reactivation in vitro [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/68\" class=\"abstract_t\">68</a>]. In this model, infection of sensory neurons with cell-associated virus leads to lytic infection; in contrast, cell-free virus establishes latency [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/68\" class=\"abstract_t\">68</a>]. During latency, the virus only expresses a limited number of viral proteins, such as immediate early protein 63 (IE63) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/72\" class=\"abstract_t\">72</a>]. Immunity to this protein may play a role in maintaining the virus in a latent state [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/73\" class=\"abstract_t\">73</a>].</p><p>VZV-specific cell-mediated immune responses play a critical role in controlling VZV latency and limiting the potential for reactivation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/2,51,74,75\" class=\"abstract_t\">2,51,74,75</a>]. A more detailed discussion of the importance of cell-mediated immunity, and how it relates to zoster vaccination, is presented elsewhere. (See <a href=\"topic.htm?path=vaccination-for-the-prevention-of-shingles-herpes-zoster#H3\" class=\"medical medical_review\">&quot;Vaccination for the prevention of shingles (herpes zoster)&quot;, section on 'Importance of cell-mediated immunity'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following varicella-zoster virus (VZV) reactivation, the dorsal spinal ganglion typically exhibits intense inflammation, accompanied by hemorrhagic necrosis of nerve cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/61\" class=\"abstract_t\">61</a>]. The ganglion undergoes eventual neuronal loss with subsequent fibrosis of afferent nerve fibers, particularly type C nociceptors [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/76\" class=\"abstract_t\">76</a>].</p><p>The dermatomal distribution of the vesicular rash of herpes zoster corresponds to the sensory fields of many infected neurons within a specific ganglion [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/2\" class=\"abstract_t\">2</a>]. Mapping of the involved sensory areas, related to each ganglion, was first conducted in 1900 in detailed autopsy studies of persons who had recent zoster [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/77\" class=\"abstract_t\">77</a>]. </p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease: one is a diffuse vesicular rash known as varicella, or chickenpox. Clinical resolution of varicella is followed by the establishment of latent infection; reactivation of this neurotropic virus may lead to herpes zoster, or &quot;shingles&quot;, a painful, unilateral vesicular eruption in a restricted dermatomal distribution. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is estimated that approximately 30 percent of persons in the United States will experience zoster during their lifetimes. Reactivation appears to be influenced by age-related immunosenescence, disease-associated immunocompromise, <span class=\"nowrap\">and/or</span> iatrogenic immunosuppression. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>People with herpes zoster can spread varicella-zoster virus (VZV) to those who have not had varicella and have never received the varicella (chickenpox) vaccine. The virus typically spreads through direct contact with the active herpes zoster lesions. However, airborne transmission of VZV from individuals with localized zoster has also been described. (See <a href=\"#H894087829\" class=\"local\">'Transmission'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>During the initial phase of varicella, VZV infects the nasopharyngeal lymphoid tissue through airborne viral droplets in a susceptible host. This is followed by rapid spread to regional lymphoid tissue via migrating T-cells. Cell-free virus, which is present only in skin vesicles, infects nerve endings in skin and migrates along sensory axons to establish latency in the regional ganglia. (See <a href=\"#H11\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Following VZV reactivation, the dorsal spinal ganglion typically exhibits intense inflammation, accompanied by hemorrhagic necrosis of nerve cells. (See <a href=\"#H14\" class=\"local\">'Pathology'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/1\" class=\"nounderline abstract_t\">Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/2\" class=\"nounderline abstract_t\">Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45:S41.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/3\" class=\"nounderline abstract_t\">Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.</a></li><li class=\"breakAll\">United States Centers for Disease Control and Prevention. Shingles Surveillance. http://www.cdc.gov/shingles/surveillance.html (Accessed on July 01, 2016).</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/5\" class=\"nounderline abstract_t\">Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/6\" class=\"nounderline abstract_t\">Straus SE, Ostrove JM, Inchausp&eacute; G, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:221.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/7\" class=\"nounderline abstract_t\">de Melker H, Berbers G, Hahn&eacute; S, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006; 24:3946.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/8\" class=\"nounderline abstract_t\">Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/9\" class=\"nounderline abstract_t\">Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/10\" class=\"nounderline abstract_t\">Gil A, San-Mart&iacute;n M, Carrasco P, Gonz&aacute;lez A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004; 22:3947.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/11\" class=\"nounderline abstract_t\">Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis 2010; 201:1024.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/12\" class=\"nounderline abstract_t\">Rimland D, Moanna A. Increasing incidence of herpes zoster among Veterans. Clin Infect Dis 2010; 50:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/13\" class=\"nounderline abstract_t\">Kawai K, Yawn BP, Wollan P, Harpaz R. Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study. Clin Infect Dis 2016; 63:221.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/14\" class=\"nounderline abstract_t\">Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4:e004833.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/15\" class=\"nounderline abstract_t\">Ragozzino MW, Melton LJ 3rd, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61:310.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/16\" class=\"nounderline abstract_t\">Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25:571.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/17\" class=\"nounderline abstract_t\">Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157:1217.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/18\" class=\"nounderline abstract_t\">Zhang JX, Joesoef RM, Bialek S, et al. Association of physical trauma with risk of herpes zoster among Medicare beneficiaries in the United States. J Infect Dis 2013; 207:1007.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/19\" class=\"nounderline abstract_t\">McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/20\" class=\"nounderline abstract_t\">Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis 2013; 56:1085.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/21\" class=\"nounderline abstract_t\">Friedman-Kien AE, Lafleur FL, Gendler E, et al. Herpes zoster: a possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals. J Am Acad Dermatol 1986; 14:1023.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/22\" class=\"nounderline abstract_t\">Opstelten W, Van Essen GA, Schellevis F, et al. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006; 16:692.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/23\" class=\"nounderline abstract_t\">Schmader K, George LK, Burchett BM, et al. Racial differences in the occurrence of herpes zoster. J Infect Dis 1995; 171:701.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/24\" class=\"nounderline abstract_t\">Dworkin RH. Racial differences in herpes zoster and age at onset of varicella. J Infect Dis 1996; 174:239.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/25\" class=\"nounderline abstract_t\">Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: Seventy-seven cases. Pediatrics 1975; 56:388.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/26\" class=\"nounderline abstract_t\">Feldhoff CM, Balfour HH Jr, Simmons RL, et al. Varicella in children with renal transplants. J Pediatr 1981; 98:25.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/27\" class=\"nounderline abstract_t\">Patti ME, Selvaggi KJ, Kroboth FJ. Varicella hepatitis in the immunocompromised adult: a case report and review of the literature. Am J Med 1990; 88:77.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/28\" class=\"nounderline abstract_t\">Carby M, Jones A, Burke M, et al. Varicella infection after heart and lung transplantation: a single-center experience. J Heart Lung Transplant 2007; 26:399.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/29\" class=\"nounderline abstract_t\">van de Beek D, Patel R, Daly RC, et al. Central nervous system infections in heart transplant recipients. Arch Neurol 2007; 64:1715.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/30\" class=\"nounderline abstract_t\">Kim DH, Messner H, Minden M, et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10:90.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/31\" class=\"nounderline abstract_t\">Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 2007; 7:741.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/32\" class=\"nounderline abstract_t\">Hovens MM, Vaessen N, Sijpkens YW, de Fijter JW. Unusual presentation of central nervous system manifestations of Varicella zoster virus vasculopathy in renal transplant recipients. Transpl Infect Dis 2007; 9:237.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/33\" class=\"nounderline abstract_t\">Korelitz BI, Fuller SR, Warman JI, Goldberg MD. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 1999; 94:424.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/34\" class=\"nounderline abstract_t\">Antonelli MA, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991; 90:295.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/35\" class=\"nounderline abstract_t\">Lyon CC, Thompson D. Herpes zoster encephalomyelitis associated with low dose methotrexate for rheumatoid arthritis. J Rheumatol 1997; 24:589.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/36\" class=\"nounderline abstract_t\">Kinder A, Stephens S, Mortimer N, Sheldon P. Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80:26.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/37\" class=\"nounderline abstract_t\">Baumgart DC, Dignass AU. Shingles following infliximab infusion. Ann Rheum Dis 2002; 61:661.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/38\" class=\"nounderline abstract_t\">Choi HJ, Kim MY, Kim HO, Park YM. An atypical varicella exanthem associated with the use of infliximab. Int J Dermatol 2006; 45:999.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/39\" class=\"nounderline abstract_t\">Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26:1544.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/40\" class=\"nounderline abstract_t\">Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166:1153.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/41\" class=\"nounderline abstract_t\">Veenstra J, Krol A, van Praag RM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995; 9:1153.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/42\" class=\"nounderline abstract_t\">Gershon AA, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 1997; 176:1496.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/43\" class=\"nounderline abstract_t\">Manuel O, Kumar D, Singer LG, et al. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008; 27:11.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/44\" class=\"nounderline abstract_t\">Arness T, Pedersen R, Dierkhising R, et al. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis 2008; 10:260.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/45\" class=\"nounderline abstract_t\">Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57:1431.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/46\" class=\"nounderline abstract_t\">Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:1483.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/47\" class=\"nounderline abstract_t\">Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/48\" class=\"nounderline abstract_t\">Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309:887.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/49\" class=\"nounderline abstract_t\">Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis 2015; 60:1269.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/50\" class=\"nounderline abstract_t\">Whitley RJ. Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. J Infect Dis 2005; 191:1999.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/51\" class=\"nounderline abstract_t\">Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325:1545.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/52\" class=\"nounderline abstract_t\">Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/53\" class=\"nounderline abstract_t\">Hales CM, Harpaz R, Joesoef MR, Bialek SR. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med 2013; 159:739.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/54\" class=\"nounderline abstract_t\">Civen R, Marin M, Zhang J, et al. Update on Incidence of Herpes Zoster Among Children and Adolescents After Implementation of Varicella Vaccination, Antelope Valley, CA, 2000 to 2010. Pediatr Infect Dis J 2016; 35:1132.</a></li><li class=\"breakAll\">The Centers for Disease Control and Prevention. Shngles (herpes zoster). http://www.cdc.gov/shingles/hcp/clinical-overview.html (Accessed on June 16, 2016).</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/56\" class=\"nounderline abstract_t\">Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 1988; 158:238.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/57\" class=\"nounderline abstract_t\">Yoshikawa T, Ihira M, Suzuki K, et al. Rapid contamination of the environments with varicella-zoster virus DNA from a patient with herpes zoster. J Med Virol 2001; 63:64.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/58\" class=\"nounderline abstract_t\">Viner K, Perella D, Lopez A, et al. Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings. J Infect Dis 2012; 205:1336.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/59\" class=\"nounderline abstract_t\">Lopez AS, Burnett-Hartman A, Nambiar R, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008; 197:646.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/60\" class=\"nounderline abstract_t\">Mehta SK, Tyring SK, Gilden DH, et al. Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis 2008; 197:654.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/61\" class=\"nounderline abstract_t\">HOPE-SIMPSON RE. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med 1965; 58:9.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/62\" class=\"nounderline abstract_t\">Ku CC, Besser J, Abendroth A, et al. Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005; 79:2651.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/63\" class=\"nounderline abstract_t\">Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1:S1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/64\" class=\"nounderline abstract_t\">Ku CC, Padilla JA, Grose C, et al. Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol 2002; 76:11425.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/65\" class=\"nounderline abstract_t\">Ku CC, Zerboni L, Ito H, et al. Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med 2004; 200:917.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/66\" class=\"nounderline abstract_t\">Satyaprakash AK, Tremaine AM, Stelter AA, et al. Viremia in acute herpes zoster. J Infect Dis 2009; 200:26.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/67\" class=\"nounderline abstract_t\">Nagel MA, Choe A, Cohrs RJ, et al. Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis 2011; 204:820.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/68\" class=\"nounderline abstract_t\">Chen JJ, Gershon AA, Li ZS, et al. Latent and lytic infection of isolated guinea pig enteric ganglia by varicella zoster virus. J Med Virol 2003; 70 Suppl 1:S71.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/69\" class=\"nounderline abstract_t\">Lungu O, Annunziato PW, Gershon A, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A 1995; 92:10980.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/70\" class=\"nounderline abstract_t\">Kennedy PG, Grinfeld E, Gow JW. Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. Proc Natl Acad Sci U S A 1998; 95:4658.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/71\" class=\"nounderline abstract_t\">Lungu O, Panagiotidis CA, Annunziato PW, et al. Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A 1998; 95:7080.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/72\" class=\"nounderline abstract_t\">Debrus S, Sadzot-Delvaux C, Nikkels AF, et al. Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol 1995; 69:3240.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/73\" class=\"nounderline abstract_t\">Sadzot-Delvaux C, Kinchington PR, Debrus S, et al. Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. J Immunol 1997; 159:2802.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/74\" class=\"nounderline abstract_t\">Burke BL, Steele RW, Beard OW, et al. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982; 142:291.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/75\" class=\"nounderline abstract_t\">Arvin AM. Aspects of the host response to varicella-zoster virus: a review of recent observations. Neurology 1995; 45:S36.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/76\" class=\"nounderline abstract_t\">Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998; 5:209.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster/abstract/77\" class=\"nounderline abstract_t\">Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900; 23:353.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8292 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Incidence</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Risk factors</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Immunocompetent hosts</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Immunocompromised patients</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">- Transplant patients</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Autoimmune disease</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- HIV infection</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">Impact of varicella vaccine on incidence of herpes zoster</a></li></ul></li><li><a href=\"#H894087829\" id=\"outline-link-H894087829\">TRANSMISSION</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">PATHOGENESIS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Dissemination and immune evasion</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Latency and reactivation</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">PATHOLOGY</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8292|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/79262\" class=\"graphic graphic_figure\">- Zoster and PHN by age</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">Clinical manifestations of varicella-zoster virus infection: Herpes zoster</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postherpetic-neuralgia\" class=\"medical medical_review\">Postherpetic neuralgia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-control-of-varicella-zoster-virus-in-hospitals\" class=\"medical medical_review\">Prevention and control of varicella-zoster virus in hospitals</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tumor-necrosis-factor-alpha-inhibitors-bacterial-viral-and-fungal-infections\" class=\"medical medical_review\">Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccination-for-the-prevention-of-chickenpox-primary-varicella-infection\" class=\"medical medical_review\">Vaccination for the prevention of chickenpox (primary varicella infection)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccination-for-the-prevention-of-shingles-herpes-zoster\" class=\"medical medical_review\">Vaccination for the prevention of shingles (herpes zoster)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=varicella-zoster-virus-infection-in-pregnancy\" class=\"medical medical_review\">Varicella-zoster virus infection in pregnancy</a></li></ul></div></div>","javascript":null}